Zynerba Pharmaceuticals Inc reports results for the quarter ended in March - Earnings Summary

Zynerba Pharmaceuticals

12/05/2021 15:43

* Zynerba Pharmaceuticals Inc  ZYNE.OQ  reported a quarterly
adjusted loss of 20 cents​​ per share for the quarter ended
in March. The mean expectation of seven analysts for the quarter
was for a loss of 25 cents per share.
* Reported revenue was zero​;  analysts expected zero. 
* Zynerba Pharmaceuticals Inc's reported EPS for the quarter was
a loss of 20 cents​.
* The mean earnings estimate of analysts had risen by
about 22.9% in the last three months.​ 
* In the last 30 days there have been no negative revisions of
earnings estimates 
* Zynerba Pharmaceuticals Inc shares had fallen by 10.5% this
quarter and gained 26.1% so far this year.
* The company reported a quarterly loss of $7.96 million.
* Wall Street's median 12-month price target for Zynerba
Pharmaceuticals Inc is $8.00 
* The current average analyst rating on the shares is "buy" and
the breakdown of recommendations is 5 "strong buy" or "buy," 2
"hold" and no "sell" or "strong sell." 
This summary was machine generated May 12 at 02:43 p.m. GMT.
​All figures in US dollars